

Zomacton® (somatropin) – Expanded indication

- On January 31, 2018, <u>Ferring Pharmaceuticals announced</u> the FDA approval of <u>Zomacton</u> (<u>somatropin</u>), for the replacement of endogenous growth hormone (GH) in adults with GH deficiency (GHD).
 - Previously, Zomacton was only indicated for the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous GH.
- GHD in adults is characterized by metabolic dysfunction, reduced physical strength and activity, altered lipid metabolism and increases in body fat. Adult GHD can be a continuation of childhood onset GHD or have an onset in adulthood resulting primarily from trauma, surgery or radiation to the head.
 - Adult GHD occurs in approximately 1 2 adults per 100,000.
- The approval of Zomacton for adult GHD is based on two studies in 98 patients with adult-onset GHD and two studies in 67 adult patients with childhood-onset GHD. Patients were randomized to another somatropin product or placebo for 6 months, followed by 12 months of treatment with another somatropin product. The primary efficacy measures were body composition (lean body mass and fat mass) and lipid parameters.
 - In patients with adult-onset GHD, treatment with another somatropin product vs. placebo resulted in an increase in mean lean body mass (2.59 vs. -0.22 kg; p < 0.001) and a decrease in body fat (-3.27 vs. 0.56 kg; p < 0.001). Similar changes were seen in childhood-onset GHD patients.</p>
 - Serum concentrations of high-density lipoprotein cholesterol had normalized by the end of 18 months of treatment with the other somatropin product (mean change of 13.7 mg/dL and 11.1 mg/dL for the adult-onset and childhood-onset groups, respectively; p < 0.001).
- The recommended dosage of Zomacton for adult patients is administered subcutaneously in one of two methods:
 - Non-weight based: Initiate Zomacton with a dose of approximately 0.2 mg/day (range, 0.15 mg/day 0.3 mg/day) and increase the dose every 1 2 months by increments of approximately 0.1 mg/day 0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 concentrations.
 - Weight based: Initiate Zomacton at 0.006 mg/kg daily and increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg daily.
 - Refer to Zomacton's drug label for further information about dosing and titration in adult patients and for pediatric dosing information.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.